NeoGenomics Inc (NEO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $2.07B
Last updated: Nov 17, 2026 at 11:06 AM ET
NeoGenomics Inc (NEO) Stock Forecast
Analysts expect NeoGenomics (NEO) to earn $0.20 per share in the fiscal year ending Dec 31, 2026, on revenue of $808.20M. Of 12 analysts, 8 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 9 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 12 ratings average 2.17, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 16.7% |
| Buy | 6 | 50.0% |
| Hold | 4 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 12
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 55.0% and revenue estimates rise 9.7%.
- Fiscal year ending Dec 31, 2026
- $0.20
- EPS consensus, revenue $808.20M
- Fiscal year ending Dec 31, 2027
- $0.31
- EPS consensus, revenue $886.92M
- Fiscal year ending Dec 31, 2028
- $0.50
- EPS consensus, revenue $964.63M
- Next report
- Feb 15, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.20 | $0.18 to $0.22 | 10 | $808.20M | $807.30M to $808.80M | 11 |
| Dec 31, 2027 | $0.31 | $0.22 to $0.39 | 11 | $886.92M | $874.70M to $892.90M | 12 |
| Dec 31, 2028 | $0.50 | -$0.23 to $1.07 | 4 | $964.63M | $964.62M to $964.63M | 6 |
Quarterly Estimates
The EPS consensus falls from $0.07 for the quarter ending Dec 31, 2026 to $0.05 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.07 | $0.05 to $0.09 | 13 | $212.06M | $200.02M to $221.76M | 13 |
| Mar 31, 2027 | $0.05 | $0.01 to $0.09 | 10 | $206.43M | $203.14M to $209.03M | 10 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 16 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 9 | 0 |
| Fiscal year ending Dec 31, 2027 | 5 | 3 |
| Quarter ending Mar 31, 2027 | 2 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 11.1% from $0.18.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.20 | $0.19 | $0.18 | $0.18 | $0.18 | +11.7% |
| Fiscal year ending Dec 31, 2027 | $0.31 | $0.34 | $0.34 | $0.34 | $0.34 | -7.0% |
| Quarter ending Mar 31, 2027 | $0.05 | $0.06 | $0.06 | $0.06 | $0.06 | -8.5% |
Frequently Asked Questions About NEO
What is the NEO stock forecast?
Consensus analyst estimates put NeoGenomics's EPS at $0.20 for the fiscal year ending Dec 31, 2026, on revenue of $808.20M. The consensus rating from 12 analysts is Buy.
How do analysts rate NEO stock?
Of 12 analysts covering NeoGenomics, 2 rate it Strong Buy, 6 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NEO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.20, with estimates from $0.18 to $0.22 from 10 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.31, with estimates from $0.22 to $0.39 from 11 analysts.
What revenue do analysts expect from NeoGenomics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $808.20M, with estimates from $807.30M to $808.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $886.92M, with estimates from $874.70M to $892.90M.
How many analysts cover NEO?
12 analysts rate NeoGenomics stock, and 10 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NEO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts